Evaluation of the Efficacy & Safety of Drospirenone in the Treatment of

Status Not yet recruiting

Clinical Trial Summary

Adenomyosis is a common benign condition of fertile women and is characterized by dysmenorrhea, hypermenorrhea, abnormal uterine bleeding, infertility and chronic pelvic pain. To date, no clear guidelines are available regarding the treatment of adenomyosis, however, resembling endometriosis, as it too is a sex hormone-dependent inflammatory condition, numerous hormonal and non-hormonal treatments are currently being used off-label in the treatment of this condition, succeeding in controlling, sometimes not fully efficiently, the resulting symptoms. Among hormonal treatments, progestins have been proposed. Decreased expression of progesterone receptors (PR) A and B has been observed in adenomyotic tissue, similar to endometriosis. Progesterone induces antiproliferative activity through binding to its receptors. The observed reduction in PR expression could partially explain the pathogenesis of adenomyosis and the poor response to progestins. Although adenomyotic tissue has lower levels of PR, a good response to high-dose topical progesterone has been demonstrated. Although several molecules have been tested, such as levonorgestrel, dienogest, and danazol, to date there are no randomized controlled trials on the use of progestins in the treatment of adenomyosis that would allow clear guidelines on their use in this setting. Among the progestins commercially available today is drospirenone, which is used clinically as a progestin in oral contraceptives. Drospirenone is a synthetic progestin similar to human progesterone and is a potent inhibitor of mineralocorticoid activity. Drospirenone has been shown to significantly reduce the diameter and maximal volume of ovarian endometrioma, reduce dysmenorrhea, reduce postoperative anatomic and symptomatic recurrence rates, and decrease serum CA125 levels. Drospirenone also acts on the endometrium, reducing its proliferation and thus improving menorrhagia symptoms and has also been shown to reduce Ki-67 expression in the human endometrium when administered orally with and without E2. Despite reports of these clinical effects on endometriosis, the direct effects of drospirenone on adenomyosis have never been tested. The aim of study is to evaluate the efficacy and safety of drospirenone in the treatment of adenomyosis, and its impact on improved quality of life and sexual life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenomyosis

Clinical Trial Details

NCT number	NCT06174792
Study type	Observational
Source	University of Palermo
Contact	Andrea Etrusco, M.D.
Phone	+39 3381614144
Email	etruscoandrea@gmail.com
Status	Not yet recruiting
Phase
Start date	December 30, 2023
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04665414` - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Recruiting	`NCT04209127` - Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis	N/A
Completed	`NCT05751876` - Dienogest in Perimenopausal Women With Adenomyosis
Recruiting	`NCT01048931` - Single-port Access Laparoscopic-assisted Vaginal Hysterectomy	Phase 3
Active, not recruiting	`NCT06223464` - Evaluation of the Relationship Between Adenomyosis and Elastographic Properties of the Cervix
Completed	`NCT05419414` - The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis	N/A
Recruiting	`NCT05152667` - Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin
Not yet recruiting	`NCT03654144` - Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis	Phase 4
Completed	`NCT01992718` - What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography	Early Phase 1
Completed	`NCT02192606` - Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?	N/A
Recruiting	`NCT02495311` - The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
Recruiting	`NCT03742843` - A Multi-omics Study of Adenomyosis
Recruiting	`NCT04481321` - Clinical and Molecular Study of Endometriosis and Adenomyosis
Recruiting	`NCT04894292` - The Effect of Adenomoyosis on Pregnancy Outcomes
Completed	`NCT03520439` - Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis	Phase 2/Phase 3
Recruiting	`NCT05937490` - Adenomyosis and ART	Phase 4
Recruiting	`NCT06373822` - New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs
Completed	`NCT01821001` - Vaginal Bromocriptine for Treatment of Adenomyosis	Phase 1
Recruiting	`NCT04295109` - Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function	N/A
Recruiting	`NCT04356664` - Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms